Neuropiln 1 (Nrp1) modulation for immune system control (SJ-13-0012)

St. Jude Reference #SJ-13-0012 


Boosting the ability of regulatory T cells by blocking an effective anti-tumor immune response led to the elimination or dramatic reduction of melanoma by the immune system in mice, without causing the autoimmune and inflammatory problems often associated with current cancer-treatment efforts that target immune regulators. The mechanism is built around two proteins. One, semaphorin-4a (Sema4a), is carried on the surface of various immune cells that can spark inflammation. The other, neuropilin-1 (Nrp1), is carried on the surface of regulatory T cells.

Related reagents


Regulatory T cell (Treg), Neuropiln 1 (Nrp1), Semaphorin-4a (Sema4a), tumor-induced tolerance, tumor resistance, autoimmune, inflammation, cancer, immunotherapeutic.

Granted patents or published applications

Related scientific references

'Regulatory T cell stability is maintained by a neuropilin-1:semaphorin-4a axis' is published on

(Abstracts are available to everyone, full text only to subscribers; relevant references are cited in the paper and can be provided on request).

Licensing opportunities

We are currently seeking nonexclusive licensing opportunities in all fields for the development of this technology.

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.